Market News & Trends
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease
Seelos Therapeutics, Inc. recently announced the initiation of a preclinical study of SLS-004 in Parkinson’s disease (PD) through an all-in-one lentiviral vector targeting the synuclein…
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase 2 Study
Atriva Therapeutics GmbH recently announced a clinical strategy to treat patients with moderate to severe COVID-19 who require hospitalization. ATR-002, an oral small molecule, has…
WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study
WindMIL Therapeutics recently announced that the first patient has been dosed in the combination therapy portion of its Phase 2 clinical trial to assess the…
ARCA Biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
ARCA biopharma, Inc. recently announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue factor (TF), as a potential treatment…
CordenPharma & Moderna Extend Strategic Manufacturing Services Agreement
CordenPharma recently announced the signing of an amendment to their existing manufacturing agreement with Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA)…
Apellis Initiates Phase 1/2 Study of APL-9 in Patients With Severe COVID-19
Apellis Pharmaceuticals, Inc. recently announced the company has initiated a Phase 1/2 clinical study of APL-9, an investigational C3 inhibitor designed for acute interventions, in…
Microfluidics Enables Reliable siRNA Drug Delivery for Inflammatory Diseases & Tumor Targeting
Researchers in the Department of Pharmacy at the Ludwig Maximilian University of Munich are using chips from Dolomite Microfluidics to reliably and consistently produce monodisperse…
Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement With Humanigen for Lenzilumab, Currently in FDA-Approved Phase 3 Study for COVID-19
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it has entered into a manufacturing agreement with Humanigen, Inc.,…
KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study
KBP Biosciences recently announced it has completed patient enrollment of BLOCK CKD (Blood Pressure in Chronic Kidney Disease), its Phase 2b study of its lead…
Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development
Alethia Biotherapeutics recently announced the US FDA has cleared its Phase 2 Investigational new drug (IND) application for AB-16B5, a potent inhibitor of the epithelial…